medigraphic.com
ISSN 0185-3252 (Print)
Revista de la Asociación Médica del Centro Médico ABC

2008, Number 4

<< Back Next >>

An Med Asoc Med Hosp ABC 2008; 53 (4)

Arterial insufficiency by ergotism

Cisneros LJC, Jáuregui CL, Rojas RGA

Language: Spanish
References: 30
Page: 202-210
PDF size: 262.27 Kb.


ABSTRACT

Ergotism, or vasospastic disease from abuse of ergotamine, is an uncommon cause of arterial insufficiency that can lead to disastrous consequences. Vasoconstriction caused by ergot alkaloids can affect small and large blood vessels, generating a myriad of symptoms due to ischemia, in any part of the body. In this article the history, mechanisms of drug toxicity, diverse forms of clinical presentation, diagnosis, complications and the available treatments for ergotamine poisoning are reviewed, beginning with the case report of a patient who was treated satisfactorily.


REFERENCES

  1. Ruano-Calderón LA, Zermeño-Pohls F. Ergotismo. Presentación de un caso y revisión de la bibliografía. Rev Neurol 2005; 40: 412-416.

  2. Harchelroad FP, Topliff AR. Ford-Clinical Toxicology. Chap 54: Ergot alkaloids. Philadelphia, PA: WB Saunders; 2001.

  3. Rusyniak DE, Furbee RB, Pascuzzi R. Historical Neurotoxins: What we have learned from toxins of the past about diseases of the present. Neuro Clin 2005; 23: 337-352.

  4. Merhoff GC, Porter JM. Ergot Intoxication: Historical review and description of unusual clinical manifestations. Am Surg 1974; 180 (5): 773-777.

  5. Eadie MJ. Convulsive ergotism: Epidemics of the serotonin syndrome? Lancet Neurol 2003; 2: 429-434.

  6. Ganetsky M, Brush DE. Serotonin syndrome-what have we learned? CPEM 2005; 04: 103-108.

  7. Evans PT, Lloyd JW. Autonomic dysaesthesia due to ergot toxicity. BMJ 1980; 281: 1621.

  8. Diener HC, Volker L. Medication-overuse headache: a worldwide problem. Lancet Neurol 2004; 3: 475-483.

  9. Pusey CD, Rainford DJ. St Anthony´s fire and pseudochronic renal failure. BMJ 1977: 935.

  10. Wammes-Van der Heijden EA, Rajimtoola H. Risk of ischemic complications related to the intensity of triptan and ergotamine use. Neurology 2006; 67: 1128-1134.

  11. Enriquez E, Rangel A. Ergotismo por automedicación. Arch Inst Cardiol Mex 2000; 70: 603-608.

  12. Schultes RE, Hoffman A. Plantas de los dioses. Origen y uso de los alucinógenos. México: FCE; 1982. p. 39-68, 102-105.

  13. Meyler WJ. Side effects of ergotamine. Cephalalgia 1996; 16: 5-10.

  14. Senter HJ, Lieberman AN, Pinto R. Cerebral manifestations of ergotism. Report of a case and review of the literature. Stroke 1976; 7: 88-92.

  15. Shepherd RFJ. Ergotism. In: White RA, Hollier LH (eds). Vascular surgery: Basic science and clinical correlations. Philadelphia: Lippincott; 1994. p. 177-191.

  16. Peroutko SJ. Drugs effective in the therapy of migraine. In: Hardman JG, Limird LE (ed). Goodman & Gillman´s The Pharmacologic Basis of Therapeutics. 9th ed. New York: McGraw-Hill; 1996. p. 487-502.

  17. Bülow PM, Ibraheem JJ, Paalgow G, Tfelt-Hansen P. Comparison of pharmacodynamic effects and plasma level of oral and rectal ergotamine. Cephalgia 1986; 6: 107-111.

  18. Perrin VL. Clinical pharmacokinetics of ergotamine in migraine and cluster headache. Clin Pharmacokinet 1985; 10: 334-352.

  19. Allonen H, Juvakoski R, Kanto J et al. Methyl ergometrine: Comparison of plasma concentrations and clinical response of two brands. Int J Clin Pharmacol Biopharm 1978; 16: 310-342.

  20. Harrison TE. Ergotaminism after a single dose of ergotamine tartrate. J Emerg Med 1984; 2: 23-25.

  21. Sanders-Bush E. Agonistas y antagonistas de los receptores de 5-hidroxitriptamina. En: Hardman JG, Limird LE. Goodman & Gillman´s Las Bases Farmacológicas de la Terapéutica. Vol 1. 10a ed. México: McGrawHill; 2003. p. 277-298.

  22. Lipton RB. Ergotamine tartarate and dihydroergotamine mesylate: safety profiles. Headache 1997; 37: 33-41.

  23. Deviere J, Reuse C. Ischemic pancreatitis and hepatitis secondary to ergotamine poisoning. J Clin Gastroenterol 1987; 9: 350-352.

  24. McKiernan TL, Bock K et al. Ergot induced peripheral vascular insufficiency, noninterventional treatment. Cathebyt Cardiovasc Diagn 1994; 31: 311.

  25. Ghali R, DeLean J et al. Erythromycin associated ergotamine intoxication: Arteriographic and electrophysiologic analysis of a rare cause of severe ischemia of the lower extremities associated with ischemic neuropathy. Ann Vasc Surg 1993; 7: 291-296.

  26. Bagby RJ, Cooper RD. Angiography in ergotism. Am J Roentgenol Radium Ther Nucl Med 1972; 116: 179-186.

  27. Kemerer VF, Dagher FJ, Osher PS. Successful treatment of ergotamine with nifedipine. AJR 1984; 143: 333-334.

  28. Ferguson JJ, Waly HM, Wilson JM. Fundamentals of coagulation and glycoprotein IIb/IIIa receptor inhibition. Eur Heart J 1998; 19 (suppl D): D3-D9.

  29. Zimran A, Ofek B, Hershko C. Treatment with captopril for peripheral ischemia induced by ergotamine. BMJ 1984; 288: 364.

  30. Levy JM, Ibrahim F, Ny Kamp PW et al. Prostaglandin E for alleviating symptoms of ergot intoxication: A case report. Cardiovasc Intervent Radiol 1984; 7: 28-30.




2020     |     www.medigraphic.com